12,130 followers
RT @FrontOncology: New research: Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC: Up to 20% of all…
RT @FrontOncology: New research: Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC: Up to 20% of all…
New research: Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC: Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase… #oncology